News Release - December 21, 2006

Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor (atorvastatin) in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied

Source: Merck

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.